Screener
Boston Scientific BSX Neuromodulation — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Boston Scientific in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 6:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000885725-26-000033
| Businesses | Three Months Ended March 31, 2026 / U.S. | Three Months Ended March 31, 2026 / Int'l | Three Months Ended March 31, 2026 / Total | Three Months Ended March 31, 2025 / U.S. | Three Months Ended March 31, 2025 / Int'l | Three Months Ended March 31, 2025 / Total |
|---|---|---|---|---|---|---|
| Endoscopy | $446 | $290 | $736 | $420 | $253 | $673 |
| Urology | 465 | 182 | 646 | 469 | 165 | 633 |
| Neuromodulation | 236 | 82 | 318 | 204 | 67 | 271 |
| MedSurg | 1,147 | 554 | 1,701 | 1,093 | 484 | 1,577 |
| Interventional Cardiology & Vascular Therapies | 552 | 692 | 1,244 | 467 | 657 | 1,124 |
| Watchman | 462 | 44 | 506 | 390 | 34 | 425 |
| Electrophysiology | 603 | 302 | 905 | 511 | 219 | 730 |
| Cardiac Rhythm Management | 349 | 229 | 578 | 358 | 220 | 578 |
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Boston Scientific's neuromodulation — net sales?
- Boston Scientific (BSX) reported neuromodulation — net sales of $318M in Q1 2026.
- How has Boston Scientific's neuromodulation — net sales changed year-over-year?
- Boston Scientific's neuromodulation — net sales increased by 17.3% year-over-year, from $271M to $318M.
- What is the long-term trend for Boston Scientific's neuromodulation — net sales?
- Over 4 years (2021 to 2025), Boston Scientific's neuromodulation — net sales has grown at a 7.2% compound annual growth rate (CAGR), from $909M to $1.2B.
- What does neuromodulation — net sales mean?
- This metric represents the total revenue generated from the sale of neuromodulation medical devices, which are used to treat chronic pain and other neurological conditions through electrical stimulation. It reflects the market adoption and commercial performance of the company's portfolio of implantable pulse generators and related therapeutic hardware. This revenue stream is a critical indicator of the company's competitive position in the interventional pain management and neuro-technology markets.
Ask your AI about Boston Scientific's neuromodulation — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude